nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program Meeting Abstract
| Authors: | Dickson, M. A.; Ravi, V.; Riedel, R. F.; Ganjoo, K. N.; Van Tine, B. A.; Chugh, R.; Cranmer, L. D.; Gordon, E. M.; Chen, J. L.; Murphy, M. C.; Schmid, A. N.; Desai, N.; Palma, N. A.; Kwiatkowski, D. J.; Wagner, A. J. |
| Abstract Title: | nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300415 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.11574 |
| Notes: | Meeting Abstract: 11574 -- This meeting was also held virtually -- Source: Wos |
